Literature DB >> 22920712

Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil.

Maria Luiza Moretti1, Plinio Trabasso, Luzia Lyra, Renata Fagnani, Mariangela Ribeiro Resende, Luis Gustavo de Oliveira Cardoso, Angélica Zaninelli Schreiber.   

Abstract

From 2006 to 2010, a retrospective study was conducted in a university referral tertiary care hospital to study the frequency and distribution of Candida species in different medical specialties. The use of mechanical ventilation, central venous catheter, and urinary catheter were recorded per 1,000 patient-days and the use of antifungals was calculated using defined daily dose (DDD). A total of 313 episodes were identified and the overall incidence was 0.54 (0.41-0.71) episodes per 1,000 patient-days. Candida albicans caused 44% of the overall episodes, followed by C. tropicalis (21.7%), C. parapsilosis (14.4%), C. glabrata (11.2%), and C. krusei (3.5%). The incidence of C. glabrata significantly increased from 2006-2010 (range: 4.8-23.5%) (P = 0.024). Candida glabrata was associated with malignancies (P = 0.004) and C. krusei with hematologic malignancies (P < 0.0001). The use of antifungals was higher in the hematology/bone marrow transplant units and represented 40% of all fluconazole prescription in the hospital. There was no correlation with the use of fluconazole and the increasing ratio of C. glabrata (r = 0.60). The use of invasive devices was significantly higher in the intensive care units (ICUs) than the medical and surgical emergencies units (P < 0.001). In contrast, the emergencies had higher incidence of candidemia (2-2.1 episodes/1,000 patient-days) than the ICUs (1.6 episodes 1,000 patient-days). Candida glabrata candidemia showed a significant increase in contrast to the current national literature where C. parapsilosis remained the most important non-C. albicans Candida species in Brazilian hospitals. Our findings suggested that the increasing incidence of C. glabrata was not associated with use of fluconazole and other risk factors might play an important role.

Entities:  

Mesh:

Year:  2012        PMID: 22920712     DOI: 10.3109/13693786.2012.708107

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  23 in total

1.  Visual analysis of DNA microarray data for accurate molecular identification of non-albicans Candida isolates from patients with candidemia episodes.

Authors:  Michela De Luca Ferrari; Mariângela Ribeiro Resende; Kanae Sakai; Yasunori Muraosa; Luzia Lyra; Tohru Gonoi; Yuzuru Mikami; Kenichiro Tominaga; Katsuhiko Kamei; Angelica Zaninelli Schreiber; Plinio Trabasso; Maria Luiza Moretti
Journal:  J Clin Microbiol       Date:  2013-06-19       Impact factor: 5.948

2.  Visible DNA Microarray System as an Adjunctive Molecular Test in Identification of Pathogenic Fungi Directly from a Blood Culture Bottle.

Authors:  Lais Lovison Sturaro; Tohru Gonoi; Ariane Fidelis Busso-Lopes; Cibele Aparecida Tararam; Carlos Emilio Levy; Luzia Lyra; Plinio Trabasso; Angélica Zaninelli Schreiber; Katsuhiko Kamei; Maria Luiza Moretti
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

3.  Temporal Trends in Blood Stream Infection Isolates from Surgical Patients.

Authors:  Christopher A Guidry; Laura H Rosenberger; Robin T Petroze; Stephen W Davies; Tjasa Hranjec; Matthew D McLeod; Amani D Politano; Lin M Riccio; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-06-12       Impact factor: 2.150

4.  Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan.

Authors:  Hazim O Khalifa; Teppei Arai; Hidetaka Majima; Akira Watanabe; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  Isolation and drug susceptibility of Candida parapsilosis sensu lato and other species of C. parapsilosis complex from patients with blood stream infections and proposal of a novel LAMP identification method for the species.

Authors:  Plinio Trabasso; Tetsuhiro Matsuzawa; Renata Fagnani; Yasunori Muraosa; Kenichiro Tominaga; Mariangela Ribeiro Resende; Katsuhiko Kamei; Yuzuru Mikami; Angelica Zaninelli Schreiber; Maria Luiza Moretti
Journal:  Mycopathologia       Date:  2014-12-07       Impact factor: 2.574

6.  Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Authors:  Fernando César Bizerra; Cristina Jimenez-Ortigosa; Ana Carolina R Souza; Giovanni Luis Breda; Flávio Queiroz-Telles; David S Perlin; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.

Authors:  Viviane Gevezier da Costa; Regina Mariuza Borsato Quesada; Aline Tancler Stipp Abe; Luciana Furlaneto-Maia; Márcia Cristina Furlaneto
Journal:  Mycopathologia       Date:  2014-08-08       Impact factor: 2.574

8.  Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells.

Authors:  Luís Vale-Silva; Françoise Ischer; Salomé Leibundgut-Landmann; Dominique Sanglard
Journal:  Infect Immun       Date:  2013-03-04       Impact factor: 3.441

Review 9.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

10.  Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of São Paulo State, Brazil.

Authors:  D K B Rodrigues; L X Bonfietti; R A Garcia; M R Araujo; J S Rodrigues; V M F Gimenes; M S C Melhem
Journal:  Braz J Med Biol Res       Date:  2021-06-14       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.